Project Grant R43DK126579

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA Program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, awarded Elixera, Inc. a $1,035,589 Project Grant (R44DK126579) to develop a novel therapeutic antibody for the treatment of acromegaly. Acromegaly is a rare endocrine disorder affecting approximately 21,000 adults in the U.S. that is often caused by a pituitary tumor. The goal of this Phase 2 grant is to prepare the therapeutic...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $1,418,424 to Tigatx Inc., a small business in Boston, Massachusetts, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers. The primary objective is to develop a first-in-class IgA-based monoclonal antibody treatment called TIGA-001 for advanced/metastatic EGFR-positive...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $235,707.00 to Weill Medical College of Cornell University to conduct research on using [68Ga]-DOTATATE PET/MRI to improve diagnostic accuracy, understand the biology of pituitary neuroendocrine tumors (PITNET), and enhance stereotactic radiosurgery (SRS) targeting for better local control and endocrine remission rates. The key products and services to be delivered...

The National Cancer Institute (NCI) awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Expression Therapeutics, Inc. to advance a promising lead cell and gene therapy candidate towards clinical testing for neuroendocrine tumors (NETs). The goal of this 1-year project is to develop an allogeneic (off-the-shelf) cell and gene therapy that utilizes Expression Therapeutics' proprietary ADEPT cell platform and STAR secreted actuator technology to display potent...

This $391,553 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to commercialize a novel alpha-particle therapy for the treatment of metastatic high-grade serous ovarian cancer (HGSOC). The funding will support Viewpoint Molecular Targeting, Inc.'s efforts to develop an image-guided alpha-particle therapy that utilizes a pretargeting approach to selectively deliver the 212Pb radioisotope to tumor cells expressing the...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $999,615 Project Grant (CFDA 93.847) to Extend Biosciences Inc. to develop a long-acting parathyroid hormone (PTH) derivative, EXT608, for the treatment of hypoparathyroidism. The goal is to evaluate whether EXT608 can restore normal serum and urinary calcium and phosphate levels in adults with hypoparathyroidism, which is a rare disease caused by a deficiency or inability to produce sufficient PTH. The...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $399,214 to Proton Bio, Inc. to perform critical proof-of-concept testing on a novel therapeutic approach targeting the proton-sensing receptor GPR68 for the treatment of glioblastoma (GBM), the most common and aggressive form of brain cancer. The key objectives are to: 1) define the in vitro pharmacological properties of three lead Ogremorphin compound...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $400,000 to Aakha Biologics, Inc. to develop a novel bispecific antibody therapy for advanced metastatic lung cancer. The funding will support research to screen and identify the optimal bispecific antibody candidate that combines three key components - an anti-MICA/B binding arm to block immune evasion, an engineered Fc variant to enhance antibody-dependent...

The National Cancer Institute (NCI) awarded Avantgen Inc., a San Diego-based biotechnology company, a $1,398,552 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to conduct preliminary IND-enabling studies and advance their program for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This research aims to address the unmet medical need for innovative treatments for these...

This Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain cancer. The $399,669 award, granted on September 3, 2024, supports the development of an antigen-agnostic ATCT platform that uses Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) to...